Best of ASCO - 2014 Annual Meeting

 

Welcome

Neuroendocrine/Carcinoid

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.

Timothy Jay Price

4102

A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).

Christian Fottner

4103

A retrospective series of centralized reviewed GEP MANECs receiving a first-line adenocarcinoma-oriented chemotherapy.

Francesca Spada

e15695

An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).

Ming-Huang Chen

4101

Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.

Jonathan R. Strosberg

4111

Antitumor efficacy of concurrent everolimus with hepatic transarterial bland embolization (evero-embo) in patients with metastatic well differentiated neuroendocrine tumor (NET).

Lowell Brian Anthony

4115

Antitumor efficacy of M3814 as a radiation sensitizer in neuroendocrine tumor (NET) preclinical models.

Aman Chauhan

e15699

Blood-based next-generation sequencing analysis of neuroendocrine tumors.

Walid Labib Shaib

4110

Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.

Salman Rafi Punekar

e15696

Circulating tumor DNA analysis of neuroendocrine tumors.

Jason Scott Starr

e15698

Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors.

Aman Chauhan

4114

Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.

Nitya Prabhakar Raj

4112

Evaluation of Ki67 and other predictors of survival in metastatic neuroendocrine tumor (NET) to the liver treated with Y90 radioembolization.

Julie Cronan

e15687

Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).

Jaume Capdevila

4106

First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.

Bhavana Konda

e15691

Geographic and demographic disparities in neuroendocrine tumors (NETs): A population-based study.

Rohit Gosain

e15694

Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.

Jorge Hernando-Cubero

4109

Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL).

Richard B. Noto

4108

Meta-analysis of prognostic biomarkers for pancreatic neuroendocrine tumors (PNETs).

Mojun Zhu

e15688

Methylation and mRNA analysis of differential genes between primary tumor and liver metastasis in pancreatic neuroendocrine neoplasm.

Mengyu Feng

e15689

Molecular characterization of the tumour microenvironment in neuroendocrine malignancy.

David James Pinato

4107

Monitoring of neuroendocrine tumors in elderly patients in the Brittany region.

Jean-Philippe Metges

e15690

NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairead Geraldine McNamara

TPS4158

Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).

Paul Girot

4104

Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma.

Frank Lin

TPS4159

Predictors of mortality following cardiac surgery for carcinoid heart disease.

Cezar Iliescu

e15692

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Emily K. Bergsland

4005

Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).

Walid Labib Shaib

e15693

Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors.

Andreja Frilling

4113

The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).

Enrique Grande

4105

Video-based patient education on carcinoid syndrome: Positive knowledge and behavior shift for patients.

Anne Roc

e15697